Yiviva

Yiviva is pioneering a novel approach to drug development by leveraging botanical formulations and systems biology to create multi-targeted therapies for complex chronic diseases and oncology. The company's lead program, YIV-906 (also known as PHY906), is a repurposed ancient herbal formula in Phase 2b trials for hepatocellular carcinoma and has shown promise in mitigating chemotherapy side effects. Founded by systems biology experts from Yale University, Yiviva combines modern computational biology with traditional medicine insights. The company is privately held, backed by venture capital, and strategically positioned to address large markets with high unmet need through a potentially safer and more efficacious therapeutic paradigm.

A systems biology and network pharmacology platform that analyzes, optimizes, and standardizes complex botanical mixtures to develop Multi-targeted Botanical Drug Candidates (MBDCs) for complex diseases.

Yiviva operates in a niche with few direct competitors developing standardized, clinically-validated botanical drugs. However, it competes indirectly with all developers of oncology therapeutics, supportive care drugs, and chronic disease therapies. Its differentiation lies in its multi-targeted, systems-based approach, which contrasts with the dominant single-target paradigm of most biopharma R&D.